

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:


**Listing of Claims:**

1                   **1-70.** (Cancel)

2                   **71.** (Currently amended and withdrawn) A pharmaceutical composition  
3 comprising a pharmaceutically acceptable excipient and a compound of any one of Claims **58**  
4 ~~and 59~~ **118 and 119.**

5                   **72-117** (Cancel)

6                   **118.** (New) A compound having a formula



7                   and their pharmaceutically acceptable salts, wherein

9                   P<sup>2</sup> is selected from the group consisting of —C(O)—, —CH(OH)—, —C(O)O—,  
10 —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —C(O)NH—, —NHC(O)—,  
11 and O(CH<sub>2</sub>CH<sub>2</sub>O)<sub>q</sub>;


12                   P<sup>3</sup> is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, aryl,  
13 heteroaryl, -NHS(O)<sub>2</sub>R<sup>2</sup>, —C(O)OR<sup>2</sup> and carboxylic acid analogs, wherein R<sup>2</sup> is a member  
14 selected from the group consisting of hydrogen, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted C<sub>1</sub>-C<sub>4</sub>  
15 alkyl, unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted aryl, substituted  
16 aryl, unsubstituted aryl C<sub>1</sub>-C<sub>4</sub> alkyl, and substituted aryl C<sub>1</sub>-C<sub>4</sub> alkyl;

17                   the subscript q is 0 to 3;

18                   L<sup>1</sup> is unsubstituted C<sub>2</sub>-C<sub>6</sub> alkylene or substituted C<sub>2</sub>-C<sub>6</sub> alkylene;

19                   L<sup>2</sup> is unsubstituted C<sub>2</sub>-C<sub>12</sub> alkylene or substituted C<sub>2</sub>-C<sub>12</sub> alkylene.

20                   **119.** (New) A compound having a formula (I):



21 and their pharmaceutically acceptable salts, wherein  
22 R<sup>1</sup> is a member selected from the group consisting of aryl and heteroaryl;  
23 P<sup>1</sup> is a primary pharmacophore selected from the group consisting of —  
24 NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —CH<sub>2</sub>C(O)NH—, —C(O)NH— and —  
25 NHC(O)—;  
26 P<sup>2</sup> is a secondary pharmacophore selected from the group consisting of —C(O)—,  
27 —CH(OH)—, —O(CH<sub>2</sub>CH<sub>2</sub>O)<sub>q</sub>—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—,  
28 —NHC(O)O—, —C(O)NH— and —NHC(O)—;  
29 P<sup>3</sup> is a tertiary pharmacophore selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>  
30 alkynyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, aryl, heteroaryl, —C(O)NHR<sup>1</sup>, —C(O)NHS(O)<sub>2</sub>R<sup>1</sup>, —NHS(O)<sub>2</sub>R<sup>2</sup>,  
31 —C(O)OR<sup>2</sup> and carboxylic acid analogs, wherein R<sup>2</sup> is a member selected from the group  
32 consisting of hydrogen, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted C<sub>3</sub>-C<sub>8</sub>  
33 cycloalkyl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl  
34 C<sub>1</sub>-C<sub>4</sub> alkyl, and substituted aryl C<sub>1</sub>-C<sub>4</sub> alkyl;  
35 the subscripts n and m are each independently 0 or 1, and at least one of n or m is  
36 1, and the subscript q is 0 to 3;  
37 L<sup>1</sup> is a first linker selected from the group consisting of unsubstituted C<sub>2</sub>-C<sub>6</sub>  
38 alkylene, substituted C<sub>2</sub>-C<sub>6</sub> alkylene, unsubstituted C<sub>3</sub>-C<sub>6</sub> cycloalkylene, substituted C<sub>3</sub>-C<sub>6</sub>  
39 cycloalkylene, unsubstituted arylene, substituted arylene, unsubstituted heteroarylene, and  
40 substituted heteroarylene; and  
41 L<sup>2</sup> is a second linker selected from the group consisting of unsubstituted C<sub>2</sub>-C<sub>12</sub>  
42 alkylene, substituted C<sub>2</sub>-C<sub>12</sub> alkylene, unsubstituted arylene, substituted arylene, and  
43 combinations thereof.  
44 120. (New) The compound according to any one of claims 118 and 119,  
45 wherein P<sup>3</sup> is —C(O)OR<sup>2</sup> or a carboxylic acid analog, wherein R<sup>2</sup> is selected from the group

47 consisting of hydrogen, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted C<sub>3</sub>-C<sub>8</sub>  
48 cycloalkyl, and substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

49           **121.** (New) The compound according to any one of Claims 118 and 119,  
50 wherein P<sup>3</sup> is -C(O)OR<sup>2</sup> or a carboxylic acid analog, wherein R<sup>2</sup> is selected from the group  
51 consisting of hydrogen, methyl, and ethyl.

52           **122.** (New) The compound of Claim 119, wherein R<sup>1</sup> is selected from the  
53 group consisting of phenyl and naphthyl.

54           **123.** (New) The compound of Claim 119, wherein R<sup>1</sup> is phenyl.

55           **124.** (New) The compound Claim 119, wherein R<sup>1</sup> is phenyl, wherein the  
56 phenyl is either unsubstituted or substituted with from one to three substituents selected from the  
57 group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, and  
58 cyano.

59           **125.** (New) The compound of Claim 119, wherein P<sup>1</sup> is selected from the  
60 group consisting of -NHC(O)CH-, -OC(O)NH-, and -NHC(O)O-.

61           **126.** (New) The compound of Claim 119, wherein P<sup>1</sup> is -NHC(O)CH-.

62           **127.** (New) The compound of Claim 119, wherein L<sup>1</sup> is an alkylene of from 2  
63 to 4 carbon atoms,

64           P<sup>2</sup> is not present; and

65           L<sup>2</sup> is an alkylene of from 2 to 8 carbon atoms.

66           **128.** (New) The compound of Claim 119, wherein P<sup>1</sup> is selected from the  
67 group consisting of —NHC(O)NH—, -OC(O)NH— and —NHC(O)O—;

68           n is 0;





69           m is 1;

70           L<sup>1</sup> is selected from the group consisting of unsubstituted C<sub>2</sub>-C<sub>6</sub> alkylene,  
71 unsubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkylene, substituted C<sub>3</sub>-C<sub>6</sub>cycloalkylene, unsubstituted arylene, and  
72 substituted arylene;


73                           L<sup>2</sup> is selected from the group consisting of unsubstituted C<sub>2</sub>-C<sub>6</sub> alkylene and  
74                           substituted C<sub>2</sub>-C<sub>6</sub> alkylene; and

75 P<sup>3</sup> is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, aryl,  
76 heteroaryl, —C(O)NHR<sup>2</sup>, —C(O)NHS(O)<sub>2</sub>R<sup>2</sup>, —NHS(O)<sub>2</sub>R<sup>2</sup>, —C(O)OR<sup>2</sup>, and carboxylic acid  
77 analogs, wherein R<sup>2</sup> is a member selected from the group consisting of hydrogen, unsubstituted  
78 C<sub>1</sub>-C<sub>4</sub> alkyl, substituted C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
79 unsubstituted aryl, substituted aryl, unsubstituted aryl C<sub>1</sub>-C<sub>4</sub> alkyl, and substituted aryl C<sub>1</sub>-C<sub>4</sub>  
80 alkyl.


81                           **129.** (New) A compound having the formula selected from the group  
82 consisting of:




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106




107




108



















109





















110






- 119      
- 120      
- 121      
- 122      
- 123      
- 124      
- 125      
- 126      


- 127      
- 128      
- 129      
- 130      
- 131      
- 132      
- 133      
- 134      
- 135      

- 136      
- 137      
- 138      
- 139      
- 140      
- 141      
- 142      
- 143      
- 144      


- 145      ,
- 146      ,
- 147      ,
- 148      ,
- 149      ,
- 150      ,
- 151      ,
- 152      ,




153




154




155




156



157



—



159

wherein Z is O or NH;

161

R<sup>3</sup> is alkyl;

162

n1 is 1, 2, 3, 4, 6, 7, 9, 10, or 11;

163

n2 is 1, 2, 3, or 4;

164

n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


165

and their pharmaceutically acceptable salts.

166

**130.** (New) A compound having the formula:


167



168

131. (New) A compound having a formula

169



170

and their pharmaceutically acceptable salts, wherein

171 P<sup>3</sup> is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, aryl,  
172 heteroaryl, -NHS(O)<sub>2</sub>R<sup>2</sup>, —C(O)OR<sup>2</sup> and carboxylic acid analogs, wherein R<sup>2</sup> is a member  
173 selected from the group consisting of hydrogen, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted C<sub>1</sub>-C<sub>4</sub>  
174 alkyl, unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted aryl, substituted  
175 aryl, unsubstituted aryl C<sub>1</sub>-C<sub>4</sub> alkyl, and substituted aryl C<sub>1</sub>-C<sub>4</sub> alkyl;

176

the subscript m is 1;

177

L<sup>1</sup> is unsubstituted C<sub>3</sub>-C<sub>4</sub> alkylene or substituted C<sub>3</sub>-C<sub>4</sub> alkylene;

178

L<sup>2</sup> is unsubstituted C<sub>8</sub> alkylene or substituted C<sub>8</sub> alkylene.

179

180

132. (New) A compound having the formula:

181

